Synaptogenix Inc (SNPX)

[InTheTrenches]

You state:

Unfortunately for Neurotrope investors, there is no indication that Bryostatin can do anything that Anavex 2-73 isn't able to do.

Fortunately for Neurotrope investors, our pre-specified subgroup analysis from a well-controlled trial showed that there's a good chance we will succeed in our current phase 2. Anavex has yet to complete a double-blind placebo-controlled trial, so 2-73 has no indication that it will do anything close to what Bryostatin is doing.

Anavex does this with a MOA of restoring cellular homeostasis, which may turn out to be a real "cure" in the end, but it's too early to know.

I agree with any comment that states it's too early to know for 2-73. In fact I think it's way too early to know if 2-73 has anything viable until we see some results from a well-controlled trial. For Alzheimer's, that's roughly 2 years out.

Anavex is looking at possible approval within a year

I would emphasize "possible"...in fact, my bet is on very unlikely.